Dato for ledelsens godkendelse af årsrapporten:2024-04-24
Beskrivelse af usikkerhed ved indregning eller måling:Uncertainty relating to recognition and measurementMeasurement of certain assets and liabilities is based on accounting estimates made by Management. These
estimates are made in accordance with the accounting policies and based on Management’s assumptions and
experience. The estimates made are considered realistic and prudent.
The areas subject to assumptions and estimates that are considered material to the financial statements are
intangible assets, investments in group enterprises, inventories and other provisions.
Inventories are subject to assumptions and estimates, as saleable straws depends on factors such as
fertility rate, pregnancy limits and donor characteristics. Inventories are measured at cost including
direct and indirect production costs. Indirect production costs are assessed on an ongoing basis to ensure
relevant and reliable measurement of these. Changes in assumptions, estimates and assessment of indirect
production costs may have an impact on the gross margin and the overall valuation of inventory.
Apart from this, there are no particular uncertainties relating to recognition and measurement.
Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Unusual circumstances affecting recognition and measurementNo significant unusual circumstances affecting recognition and measurement have occurred.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The Executive Board has today considered and approved the annual report of PW Estournel Holding III ApS for the financial year 01. 01. 2023 - 31. 12. 2023.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesThe Group’s main activities are within the fertility industry and related production.
PW Estournel acquired European Sperm Bank (ESB) in August 2022. Founded in 2004, ESB is one of the leading sperm banks in the world, providing fertility clinics all over the world with donor semen of the highest quality. The
main product offering consists of a wide selection of high-quality donor semen from both open and anonymous sperm donors, helping heterosexual couples, single women and lesbian couples in +100 countries. The end users are reached through two channels, i. e. the products are either sold to a fertility clinic (B2B) or directly to end customers via the company website
(B2C), in which case the donor semen is delivered to a clinic of choice where the fertility treatment is carried out.
ESB is headquartered in Copenhagen with c. 120 employees worldwide and currently operates out of 9 locations,
including 3 sites in Copenhagen (DK), 1 site in Åhus, 1 site in Ålborg (DK), 1 site in the Nederlands (NL), 1 site in London (UK) and 2 site in Hamburg (DE).
The parent company’s main activities are investments in subsidiaries within the fertility industry and related
production, including providing management services.